CL2022000115A1 - Terapia genética cardíaca con aav para la cardiomiopatía en humanos. - Google Patents
Terapia genética cardíaca con aav para la cardiomiopatía en humanos.Info
- Publication number
- CL2022000115A1 CL2022000115A1 CL2022000115A CL2022000115A CL2022000115A1 CL 2022000115 A1 CL2022000115 A1 CL 2022000115A1 CL 2022000115 A CL2022000115 A CL 2022000115A CL 2022000115 A CL2022000115 A CL 2022000115A CL 2022000115 A1 CL2022000115 A1 CL 2022000115A1
- Authority
- CL
- Chile
- Prior art keywords
- cardiac
- humans
- compositions
- methods
- cardiomyopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22061—Caspase-8 (3.4.22.61)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se relaciona con composiciones y métodos útiles en el tratamiento de afecciones cardíacas. Las composiciones y métodos divulgados se basan en terapias génicas que comprenden un vector de AAV recombinante para el suministro de dos o más transgenes en el corazón de un sujeto humano, en donde los transgenes comprenden una proteína S100A1 y un Represor de la Apoptosis cardíaca con un inhibidor apoptótico del Dominio de Reclutamiento de Caspasas (cARC). En diversas realizaciones, las composiciones y los métodos divulgados en la presente comprenden vectores que constan de secuencias de ADNc de cARC y/o S100A1 que son optimizados con codones para la expresión en humanos. En algunos aspectos, la focalización en múltiples fuentes de una o más afecciones cardíacas puede proporcionar beneficios sinérgicos durante el tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962876540P | 2019-07-19 | 2019-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000115A1 true CL2022000115A1 (es) | 2022-10-07 |
Family
ID=74193792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000115A CL2022000115A1 (es) | 2019-07-19 | 2022-01-17 | Terapia genética cardíaca con aav para la cardiomiopatía en humanos. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220265858A1 (es) |
EP (1) | EP3999074A4 (es) |
JP (1) | JP2022541793A (es) |
KR (1) | KR20220034801A (es) |
CN (1) | CN114206351A (es) |
AR (1) | AR122289A1 (es) |
AU (1) | AU2020316339A1 (es) |
BR (1) | BR112022000898A2 (es) |
CA (1) | CA3142534A1 (es) |
CL (1) | CL2022000115A1 (es) |
CO (1) | CO2022001686A2 (es) |
IL (1) | IL289667A (es) |
MX (1) | MX2022000767A (es) |
SG (1) | SG11202112140SA (es) |
TW (1) | TW202117017A (es) |
WO (1) | WO2021016126A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022140402A1 (en) * | 2020-12-23 | 2022-06-30 | University Of Florida Research Foundation, Incorporated | Increased packaging efficiency of vector for cardiac gene therapy |
WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002216751A1 (en) * | 2000-06-30 | 2002-01-14 | Collateral Therapeutics, Inc. | Dual recombinant gene therapy compositions and methods of use |
WO2008054713A2 (en) * | 2006-10-30 | 2008-05-08 | Thomas Jefferson University | Tissue specific gene therapy treatment |
EP2295072A1 (en) * | 2009-09-15 | 2011-03-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Use of ARC for inhibiting cell death during liver failure |
EP3452101A2 (en) * | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
US20200308582A1 (en) * | 2017-10-12 | 2020-10-01 | Universität Heidelberg | Kcnk3-based gene therapy of cardiac arrhythmia |
CN112272705A (zh) * | 2018-06-08 | 2021-01-26 | 佛罗里达大学研究基金会有限公司 | 用于心肌病的aav心脏基因治疗 |
-
2020
- 2020-07-17 SG SG11202112140SA patent/SG11202112140SA/en unknown
- 2020-07-17 JP JP2022503802A patent/JP2022541793A/ja active Pending
- 2020-07-17 KR KR1020227002673A patent/KR20220034801A/ko unknown
- 2020-07-17 AU AU2020316339A patent/AU2020316339A1/en active Pending
- 2020-07-17 EP EP20844818.3A patent/EP3999074A4/en active Pending
- 2020-07-17 AR ARP200102021A patent/AR122289A1/es unknown
- 2020-07-17 MX MX2022000767A patent/MX2022000767A/es unknown
- 2020-07-17 CN CN202080052456.6A patent/CN114206351A/zh active Pending
- 2020-07-17 BR BR112022000898A patent/BR112022000898A2/pt unknown
- 2020-07-17 US US17/628,139 patent/US20220265858A1/en active Pending
- 2020-07-17 TW TW109124287A patent/TW202117017A/zh unknown
- 2020-07-17 WO PCT/US2020/042663 patent/WO2021016126A1/en active Application Filing
- 2020-07-17 CA CA3142534A patent/CA3142534A1/en active Pending
-
2022
- 2022-01-06 IL IL289667A patent/IL289667A/en unknown
- 2022-01-17 CL CL2022000115A patent/CL2022000115A1/es unknown
- 2022-02-17 CO CONC2022/0001686A patent/CO2022001686A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021016126A1 (en) | 2021-01-28 |
EP3999074A4 (en) | 2023-08-16 |
AU2020316339A1 (en) | 2021-11-18 |
CO2022001686A2 (es) | 2022-03-29 |
BR112022000898A2 (pt) | 2022-06-07 |
CN114206351A (zh) | 2022-03-18 |
KR20220034801A (ko) | 2022-03-18 |
WO2021016126A8 (en) | 2021-09-10 |
TW202117017A (zh) | 2021-05-01 |
CA3142534A1 (en) | 2021-01-28 |
JP2022541793A (ja) | 2022-09-27 |
AU2020316339A2 (en) | 2021-11-25 |
MX2022000767A (es) | 2022-04-25 |
AR122289A1 (es) | 2022-08-31 |
SG11202112140SA (en) | 2021-11-29 |
IL289667A (en) | 2022-03-01 |
EP3999074A1 (en) | 2022-05-25 |
US20220265858A1 (en) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000115A1 (es) | Terapia genética cardíaca con aav para la cardiomiopatía en humanos. | |
CO2020016718A2 (es) | Terapia génica cardíaca con aav para cardiomiopatía | |
CL2021001058A1 (es) | Proteínas heterodiméricas fusionadas con fc | |
PE20211419A1 (es) | Vectores virales recombinantes y acidos nucleicos para producirlos | |
PE20181922A1 (es) | Terapia genica para tratar la hemofilia a | |
CO2020010376A2 (es) | Uso de vectores lentivirales que expresan el factor viii | |
UY37636A (es) | Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1 | |
CL2021003096A1 (es) | Partículas virales modificadas y usos de estas | |
AR116700A1 (es) | Generación de una mejor fenilalanina hidroxilasa hepática humana para el tratamiento de la fenilcetonuria severa por terapia génica de reemplazo directo en el hígado | |
MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
CO2021016487A2 (es) | Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth | |
EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
ECSP20055797A (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
CL2022003147A1 (es) | Composiciones y métodos para tratar pérdida auditiva asociada con gjb2 | |
CO2023006811A2 (es) | Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca | |
CO2022006772A2 (es) | Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno | |
BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer | |
AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
EA202092654A1 (ru) | Генная терапия сердца с помощью aav при кардиомиопатии | |
CO2018007251A2 (es) | Métodos y composiciones para el tratamiento del síndrome de hunter | |
EA202192964A1 (ru) | Комбинированная терапия | |
DOP2023000132A (es) | Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
ECSP23093588A (es) | Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva |